![]()
|
|
|
Jubilant announces collaboration with Mnemosyne
April 2012
SHARING OPTIONS:
BANGALORE, India—A new drug discovery collaboration was established
last month between Jubilant Biosys Ltd. and Mnemosyne Pharmaceutical Inc.
focused on identifying preclinical candidates in neuropsychiatric diseases. The
companies will work to develop subunit selective NMDA receptor modulators
(SNRMs) identified by Mnemosyne, and the collaboration will initially run for
two years, though it can be extended by mutual consent across other therapeutic
areas. Per the terms of the agreement, Mnemosyne will have exclusive ownership
of all intellectual property generated and will be responsible for clinical
development and commercialization within the partnership.
“We are looking forward to a successful collaboration with
Jubilant that will produce first-in-class drugs that address the unmet medical
need in neuropsychiatric diseases such as schizophrenia and Alzheimer's
disease,” Dr. Kollol Pal, CEO of Mnemosyne, said in a press release. Back |
|
||
|
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|